DaVita Inc. Q1 2025 10-Q Summary
Business Context and Reporting Period
This summary covers DaVita Inc.'s (NYSE: DVA) unaudited financial results for the quarterly period ended March 31, 2025. DaVita is a leading provider of kidney dialysis services in the United States, operating through its U.S. dialysis segment and ancillary services (including Integrated Kidney Care and international operations). The company reported approximately 75.5 million shares of common stock outstanding as of May 9, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 | Change |
|---|---|---|---|
| Total Revenues | $3,223.5 million | $3,070.6 million | +5.0% |
| Operating Income | $438.9 million | $483.8 million | -9.3% |
| Net Income (DaVita Inc.) | $162.9 million | $239.6 million | -32.0% |
| Diluted EPS | $2.00 | $2.65 | -24.5% |
| Operating Cash Flow | $180.0 million | ($134.8 million) | Significant Improvement |
| Free Cash Flow | ($45.0 million) | ($327.0 million) | Improvement |
| Total Debt (Principal) | $9,799.4 million | $9,511.1 million (Dec 2024) | Increased |
| Cash & Equivalents | $438.8 million | $794.9 million (Dec 2024) | Decreased |
Note: Debt expense for Q1 2025 was $135.1 million, reflecting a weighted average effective interest rate of 5.60%.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 5.0% year-over-year, driven by a 2.4% increase in U.S. dialysis revenues and a 21.3% increase in ancillary services. U.S. dialysis revenue growth was supported by a 4.1% increase in average patient service revenue per treatment, primarily due to the incorporation of phosphate binders into the ESRD PPS bundle and Medicare rate increases.
- Profitability Decline: Operating income decreased 9.3% year-over-year. This was primarily due to higher operating costs (pharmaceuticals, compensation, medical supplies) and a decrease in dialysis treatment volumes (down 1.6% YoY) caused by elevated patient mortality rates from a severe flu season and missed treatments due to weather events.
- Non-Recurring Items: Q1 2024 included a $35.1 million non-cash gain on changes in ownership interests, which was absent in Q1 2025, contributing to the lower year-over-year operating income comparison.
- Cash Flow Recovery: Operating cash flow turned positive ($180.0 million) compared to a negative $134.8 million in Q1 2024. The improvement was largely due to better collections compared to Q1 2024, which was adversely impacted by the Change Healthcare cybersecurity breach.
Outlook, Risks, and Unusual Items
- Cybersecurity Incident: On April 12, 2025, DaVita experienced a ransomware incident. While the company has restored most functions and prioritized patient care, it cannot yet estimate the full financial impact or duration of disruption. Data exfiltration involving PII/PHI is under investigation.
- Share Repurchases: The company repurchased 3.66 million shares for $550.2 million in Q1 2025. As of May 12, 2025, approximately $1.13 billion remained available under the current authorization.
- Legal Proceedings: The company is subject to various investigations, including a 2020 U.S. Attorney investigation (motion to dismiss denied in April 2025), a California Department of Insurance investigation, and an FTC antitrust investigation regarding medical director services.
- Operational Risks: Management cites risks related to labor market conditions, union organizing activities, supply chain disruptions, and the potential impact of new U.S. administration policies on healthcare reimbursement.
Investor Verification Checklist
- Cybersecurity Impact: Monitor subsequent filings for updates on the April 2025 ransomware incident, specifically regarding insurance coverage for remediation costs and any regulatory fines.
- Phosphate Binder Reimbursement: Verify the sustainability of the revenue uplift from the ESRD PPS bundle inclusion of phosphate binders and the duration of the Transitional Drug Add-on Payment Adjustment (TDAPA).
- Debt Service Capacity: Review the company's ability to service its ~$9.8 billion debt load given the increased interest expense and the recent draw on the revolving credit facility ($425 million).
- Legal Accruals: Assess the potential financial exposure from the denied motion to dismiss in the U.S. ex rel. Bayne v. DaVita Inc. case and ongoing FTC investigations.
- Noncontrolling Interests: Note the significant noncontrolling interest subject to put provisions ($1.67 billion) and the associated valuation risks tied to EBITDA multiples.